Drug Profile
Research programme: tetracosactide - Travere Therapeutics
Alternative Names: 1-24-Corticotropin - Travere Therapeutics; ACTH (1-24) - Travere Therapeutics; Cosyntropin - Travere Therapeutics; RE-034Latest Information Update: 24 Nov 2020
Price :
$50
*
At a glance
- Originator Retrophin
- Developer Travere Therapeutics
- Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infantile spasms; Nephrotic syndrome
Most Recent Events
- 16 Nov 2020 Retrophin is now called Travere Therapeutics
- 28 Jul 2018 No recent reports of development identified for preclinical development in Infantile spasms in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Nephrotic-syndrome in USA (Parenteral)